Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.
about
A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology GroupGenetic studies of a cluster of acute lymphoblastic leukemia cases in Churchill County, NevadaOsteonecrosis in children with acute lymphoblastic leukemiaPharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical UsePharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapyChildhood Acute Lymphoblastic Leukemia: Progress Through CollaborationInfluence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia.Microarray‑based screening of differentially expressed genes in glucocorticoid‑induced avascular necrosis.Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALLBone morbidity in childhood leukemia: epidemiology, mechanisms, diagnosis, and treatmentPrevalence of osteonecrosis and associated risk factors in children before allogeneic BMT.Improved prognosis for older adolescents with acute lymphoblastic leukemia.Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.Age-dependent changes in health status in the Childhood Cancer Survivor cohortUtility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoids.Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivorsAvascular necrosis in pediatric systemic lupus erythematosus: a brief report and review of the literature.Inherited genetic variation in childhood acute lymphoblastic leukemia.Screening and management of adverse endocrine outcomes in adult survivors of childhood and adolescent cancer.Ancestry and pharmacogenetics of antileukemic drug toxicityAsparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse ModelGenetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemiaPharmacogenomics of adverse effects of anti-leukemic agents in children.Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trialUnique MRI findings as an early predictor of osteonecrosis in pediatric acute lymphoblastic leukemia.Osteonecrosis in children after therapy for malignancy.Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.Vertebral compression fractures during chemotherapy for childhood acute lymphoblastic leukemia: commentary on a report from the STeroid Associated Osteoporosis in the Pediatric Population (STOPP) research program.The pharmacogenetics research network: from SNP discovery to clinical drug response.Incidence and outcome of osteonecrosis in children and adolescents after intensive therapy for acute lymphoblastic leukemia (ALL).Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations.Milestones in the curability of pediatric cancersPharmacogenetics of acute lymphoblastic leukemia treatment response.Risk factors for symptomatic osteonecrosis in childhood ALL: A retrospective study of a Slovenian pediatric ALL population between 1970 and 2004.The adolescent and young adult with cancer: state of the art-- acute leukemias.Pharmacogenetics in acute lymphoblastic leukemia.Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings.Chronic health conditions in childhood cancer survivors: is it all treatment-related--or do genetics play a role?Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.Pharmacogenomics of pediatric acute lymphoblastic leukemia.
P2860
Q24656610-BE1B86A1-EE0C-48CC-BD7D-D53FDBC6C4BCQ24682265-A030E5D6-9E18-479C-A01E-03D4D7003FDEQ28066799-19732A72-C9D4-4A7C-B2F2-5C9BD6C3A1D6Q28068930-9E86046B-5746-4531-AA36-C7ED58EFF286Q28083449-0BD93D2B-E1B9-4E2E-8A14-AFB7EAEFCCE9Q28087637-C39C7411-CDCD-4A4C-8D81-F19EAB55D7AEQ33398162-19CEC5F2-E251-4FDC-8755-CFBE05940D2DQ33702066-2ED33543-62EF-4B6D-9CD9-DA9E807AE9A8Q33925128-4FFC2D33-045A-44DA-987D-46790CC06C26Q34038283-C897D49F-FF4C-487B-8B2E-814393DD99C4Q34440965-7E888047-6702-4D2E-A18D-23E6256E80C1Q34679298-8EEF432E-1592-4CB6-95B2-B7371BF91A9DQ34707586-E225BD5F-28D0-4917-AC61-638C8ED373EBQ35040691-54429B1B-99DA-4732-9263-92FFE935D354Q35065477-BD4601AB-65FE-4C4A-8A7F-FD2BA698A063Q35327266-5185B27D-56BE-4D53-ABE3-9290699DB0EFQ35555709-2F6C2E24-B568-4F95-BF9C-22E5D80F850BQ35784497-8A349E28-CC8D-4127-B507-2439AB798243Q35815806-A7EAA9DF-3E3C-4CCF-90DD-583CFFA53281Q35828717-82D3105C-588D-452F-BE4B-D83D3CC8C246Q35954058-EFF0D8F6-EAAA-4C80-A3C7-6B31ABF28A96Q36143232-2B4DB15C-BE66-4EC9-882B-F50C772ADF4CQ36191097-D2AD36C3-1773-4CCE-9B19-C38D70C1A00BQ36251056-0C7B69B9-34BC-49DE-BECA-00EB0319C4F6Q36422310-5F752591-C3F1-4FEA-9C65-6934D54433C7Q36429353-5773A48C-ABB0-4F8E-A642-58D40DFB48DDQ36452241-81494B78-C1C1-464A-A060-1F9C5F371841Q36508158-0D05EF8A-BEE9-4E6A-B1F7-73D37476F146Q36752662-659BDEAE-9EDB-470B-9CF4-C595E6D69ABBQ36895136-846942BF-AB33-41C9-95C2-811BDF841E66Q36909252-5F00CAA6-B3A1-4832-AE3E-5F49BB17DDEEQ36925083-FAD38F1E-3DEC-495C-8A20-CC667AFCC429Q36968156-9522A065-B292-46BA-B2B0-B59E1F36AC89Q37106645-98B03CD2-0161-40B9-AF33-576081719C3CQ37134753-063DEE87-26C1-4548-BA35-35F9ABAA3E3DQ37150913-59EEF589-2241-4409-A53E-DFB290B7F30CQ37181682-048099CE-4FC4-4D9E-86A1-6B618945396FQ37390119-84561544-A8BA-4672-B008-ED7FA843C168Q37414183-DC9897B4-9D05-4F14-A5B8-083D6B089908Q37739432-00E771AA-B582-42FC-A4EF-3CF6A23F422A
P2860
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.
@en
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.
@nl
type
label
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.
@en
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.
@nl
prefLabel
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.
@en
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.
@nl
P2093
P356
P1476
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.
@en
P2093
Gary L Rosner
John T Sandlund
Mary V Relling
Michael Neel
Raul Ribeiro
Scott Howard
Sue C Kaste
Wenjian Yang
P304
P356
10.1200/JCO.2004.11.020
P407
P577
2004-10-01T00:00:00Z